ArticleMolecular pharmaceutics2012

Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.

Jonathan E Constance et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.